Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | HPGDS | O60760 | 2/20 | 0.48 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CFD | P00746 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1114473 | 0.92 | KMT2A (0.54) | SMN1; SMN2LMNAMAPTKMT2AKDM4E | |
| SCHEMBL1114211 | 0.90 | HPGDS (0.48) | SMN1; SMN2LMNAMAPTKMT2AKDM4E | |
| SCHEMBL1114791 | 0.88 | KMT2A (0.49) | SMN1; SMN2LMNAMAPTKMT2AKDM4E | |
| SCHEMBL3240443 | 0.86 | SMPD1 (0.57) | SMN1; SMN2LMNAMAPTKMT2AKDM4E | |
| SCHEMBL3240322 | 0.85 | SMN1; SMN2 (0.57) | SMN1; SMN2LMNAMAPTKMT2AKDM4E | |
| SCHEMBL1114330 | 0.84 | KMT2A (0.51) | SMN1; SMN2LMNAMAPTKMT2AKDM4E | |
| SCHEMBL1114527 | 0.84 | KMT2A (0.53) | SMN1; SMN2LMNAMAPTKMT2AKDM4E | |
| SCHEMBL3247033 | 0.83 | KMT2A (0.46) | SMN1; SMN2LMNAMAPTKMT2AKDM4E | |
| SCHEMBL1114835 | 0.83 | SMPD1 (0.58) | SMN1; SMN2LMNAMAPTKMT2AKDM4E | |
| SCHEMBL692220 | 0.82 | HIF1A (0.47) | SMN1; SMN2MAPTLIPGAOC3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2278879-B1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING OXADIAZOLE DERIVATIVES | PATH DRUG SOLUTIONS (US) | 2016-06-15 | — | — | EP | claimed |
| US-8207205-B2 | Compounds, compositions and methods comprising oxadiazole derivatives | INSTITUTE FOR ONEWORLD HEALTH (US) | 2012-06-26 | — | — | US | claimed |
| US-20090264441-A1 | Compounds, Compositions and Methods Comprising Oxadiazole Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-10-22 | — | — | US | claimed |
| EP-2278879-B1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING OXADIAZOLE DERIVATIVES | PATH DRUG SOLUTIONS (US) | 2016-06-15 | — | — | EP | disclosed |
| US-8796321-B2 | Compounds, compositions and methods comprising oxadiazole derivatives | PATH DRUG SOLUTIONS (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796321-B2 | Compounds, compositions and methods comprising oxadiazole derivatives | PATH DRUG SOLUTIONS (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796321-B2 | Compounds, compositions and methods comprising oxadiazole derivatives | PATH DRUG SOLUTIONS (US) | 2014-08-05 | — | — | US | disclosed |
| US-20120264717-A1 | Compounds, Compositions and Methods Comprising Oxadiazole Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2012-10-18 | — | — | US | disclosed |
| US-20120264717-A1 | Compounds, Compositions and Methods Comprising Oxadiazole Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2012-10-18 | — | — | US | disclosed |
| US-20120264717-A1 | Compounds, Compositions and Methods Comprising Oxadiazole Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2012-10-18 | — | — | US | disclosed |
| US-8207205-B2 | Compounds, compositions and methods comprising oxadiazole derivatives | INSTITUTE FOR ONEWORLD HEALTH (US) | 2012-06-26 | — | — | US | disclosed |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-06-10 | — | — | US | disclosed |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-06-10 | — | — | US | disclosed |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-06-10 | — | — | US | disclosed |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-12-24 | — | — | US | disclosed |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-12-24 | — | — | US | disclosed |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-12-24 | — | — | US | disclosed |
| US-20090264441-A1 | Compounds, Compositions and Methods Comprising Oxadiazole Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-10-22 | — | — | US | disclosed |
| US-20090264441-A1 | Compounds, Compositions and Methods Comprising Oxadiazole Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-10-22 | — | — | US | disclosed |
| US-20090264441-A1 | Compounds, Compositions and Methods Comprising Oxadiazole Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | CFTR, PKD1, PKD2 | SMN1; SMN2 4546/4885LMNA 3364/4885MAPT 4877/4885 |
| US-20090264441-A1 | Compounds, Compositions and Methods Comprising Oxadiazole Derivatives | CFTR, PKD1, PKD2 | SMN1; SMN2 3726/4885LMNA 4567/4885MAPT 4856/4885 |
| US-20120264717-A1 | Compounds, Compositions and Methods Comprising Oxadiazole Derivatives | CFTR, PKD1, PKD2 | SMN1; SMN2 3726/4885LMNA 4567/4885MAPT 4856/4885 |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | CFTR, PKD1, PKD2 | SMN1; SMN2 4546/4885LMNA 3364/4885MAPT 4877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.